204 related articles for article (PubMed ID: 33649523)
1. Single nucleotide polymorphisms to predict taxanes toxicities and effectiveness in cancer patients.
Demurtas S; La Verde N; Rota S; Casazza G; Montrasio C; Cheli S; Cona MS; Dalu D; Fasola C; Ferrario S; Filipazzi V; Gambaro A; Tosca N; Clementi E
Pharmacogenomics J; 2021 Aug; 21(4):491-497. PubMed ID: 33649523
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetic Approach to Toxicity in Breast Cancer Patients Treated with Taxanes.
Angelini S; Botticelli A; Onesti CE; Giusti R; Sini V; Durante V; Strigari L; Gentile G; Cerbelli B; Pellegrini P; Sgroi V; Occhipinti M; DI Pietro FR; Rossi A; Simmaco M; Mazzuca F; Marchetti P
Anticancer Res; 2017 May; 37(5):2633-2639. PubMed ID: 28476838
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: A systematic review.
Frederiks CN; Lam SW; Guchelaar HJ; Boven E
Cancer Treat Rev; 2015 Dec; 41(10):935-50. PubMed ID: 26585358
[TBL] [Abstract][Full Text] [Related]
4. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel.
Henningsson A; Marsh S; Loos WJ; Karlsson MO; Garsa A; Mross K; Mielke S; Viganò L; Locatelli A; Verweij J; Sparreboom A; McLeod HL
Clin Cancer Res; 2005 Nov; 11(22):8097-104. PubMed ID: 16299241
[TBL] [Abstract][Full Text] [Related]
5. Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms.
Tsai SM; Lin CY; Wu SH; Hou LA; Ma H; Tsai LY; Hou MF
Clin Chim Acta; 2009 Jun; 404(2):160-5. PubMed ID: 19332043
[TBL] [Abstract][Full Text] [Related]
6. SNPs and taxane toxicity in breast cancer patients.
Bosó V; Herrero MJ; Santaballa A; Palomar L; Megias JE; de la Cueva H; Rojas L; Marqués MR; Poveda JL; Montalar J; Aliño SF
Pharmacogenomics; 2014; 15(15):1845-58. PubMed ID: 25495407
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese.
Tanabe Y; Shimizu C; Hamada A; Hashimoto K; Ikeda K; Nishizawa D; Hasegawa J; Shimomura A; Ozaki Y; Tamura N; Yamamoto H; Yunokawa M; Yonemori K; Takano T; Kawabata H; Tamura K; Fujiwara Y
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1179-1186. PubMed ID: 28447211
[TBL] [Abstract][Full Text] [Related]
8. Association between gene polymorphism and adverse effects in cancer patients receiving docetaxel treatment: a meta-analysis.
Yan M; Fan X; Si H; Wang X; Wang Z; Wang Z; Lv X; Yin H; Jia Y; Jiang L; Xia Y; Liu Y
Cancer Chemother Pharmacol; 2022 Feb; 89(2):173-181. PubMed ID: 34988655
[TBL] [Abstract][Full Text] [Related]
9. Adverse Event Profile for Nanoparticle Albumin-Bound Paclitaxel Compared With Solvent-Based Taxanes in Solid-Organ Tumors: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
He F; Liu J; Shen X; Wang Z; Li Q; Li G
Ann Pharmacother; 2022 Aug; 56(8):898-909. PubMed ID: 34963337
[TBL] [Abstract][Full Text] [Related]
10. Single-nucleotide polymorphism associations with efficacy and toxicity in metastatic castration-resistant prostate cancer treated with cabazitaxel.
Herrero Rivera D; Vacas CG; Kovandzic LM; Vázquez JP; Alonso LA; González BM; Aragón VC; Grande E; Caro RL; Virizuela Echaburu JA; Rodríguez Moreno JF; Etxebarria AA; Rodríguez-Antona C; Durán I
Pharmacogenomics; 2022 Jul; 23(11):627-638. PubMed ID: 35880554
[No Abstract] [Full Text] [Related]
11. Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer.
Gréen H; Söderkvist P; Rosenberg P; Mirghani RA; Rymark P; Lundqvist EA; Peterson C
Basic Clin Pharmacol Toxicol; 2009 Feb; 104(2):130-7. PubMed ID: 19143748
[TBL] [Abstract][Full Text] [Related]
12. The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients.
Chew SC; Singh O; Chen X; Ramasamy RD; Kulkarni T; Lee EJ; Tan EH; Lim WT; Chowbay B
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1471-8. PubMed ID: 21468756
[TBL] [Abstract][Full Text] [Related]
13. Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer.
Bergmann TK; Gréen H; Brasch-Andersen C; Mirza MR; Herrstedt J; Hølund B; du Bois A; Damkier P; Vach W; Brosen K; Peterson C
Eur J Clin Pharmacol; 2011 Jul; 67(7):693-700. PubMed ID: 21327421
[TBL] [Abstract][Full Text] [Related]
14. Association of Allelic Interaction of Single Nucleotide Polymorphisms of Influx and Efflux Transporters Genes With Nonhematologic Adverse Events of Docetaxel in Breast Cancer Patients.
Jabir RS; Ho GF; Annuar MABA; Stanslas J
Clin Breast Cancer; 2018 Oct; 18(5):e1173-e1179. PubMed ID: 29885788
[TBL] [Abstract][Full Text] [Related]
15. Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 92 women with ovarian cancer.
Bergmann TK; Brasch-Andersen C; Gréen H; Mirza MR; Skougaard K; Wihl J; Keldsen N; Damkier P; Peterson C; Vach W; Brøsen K
Basic Clin Pharmacol Toxicol; 2012 Feb; 110(2):199-204. PubMed ID: 21955855
[TBL] [Abstract][Full Text] [Related]
16. Metabolism of the taxanes including nab-paclitaxel.
Joerger M
Expert Opin Drug Metab Toxicol; 2015 May; 11(5):691-702. PubMed ID: 25394848
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel.
Vivaldi C; Crucitta S; Catanese S; Cucchiara F; Arrigoni E; Pecora I; Rofi E; Fornaro L; Salani F; Massa V; Vasile E; Morganti R; Danesi R; Del Re M
Pharmacogenomics J; 2021 Apr; 21(2):233-242. PubMed ID: 33462346
[TBL] [Abstract][Full Text] [Related]
18. CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity.
de Graan AJ; Elens L; Sprowl JA; Sparreboom A; Friberg LE; van der Holt B; de Raaf PJ; de Bruijn P; Engels FK; Eskens FA; Wiemer EA; Verweij J; Mathijssen RH; van Schaik RH
Clin Cancer Res; 2013 Jun; 19(12):3316-24. PubMed ID: 23640974
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics of taxanes: impact of gene polymorphisms of drug transporters on pharmacokinetics and toxicity.
Jabir RS; Naidu R; Annuar MA; Ho GF; Munisamy M; Stanslas J
Pharmacogenomics; 2012 Dec; 13(16):1979-88. PubMed ID: 23215890
[TBL] [Abstract][Full Text] [Related]
20. CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel.
Hertz DL; Motsinger-Reif AA; Drobish A; Winham SJ; McLeod HL; Carey LA; Dees EC
Breast Cancer Res Treat; 2012 Jul; 134(1):401-10. PubMed ID: 22527101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]